Monoclonal Antibody Pipeline Focused on Oncology

Dedicated to changing patients’ lives.

Learn More

Better Life Through Better Science

KaloBios is developing proprietary customized, targeted, first-in-class monoclonal antibodies designed to significantly improve the care of seriously ill patients with cancer.

Recent Corporate Highlights

  • Initiated Phase 2 expansion portion of clinical trial for KB004 in hematologic malignancies
  • Announced preliminary Phase 1 results in advanced hematologic malignancies with KB004 at ASH Annual Meeting

Read All

Latest News

November 19, 2015

KaloBios Pharmaceuticals, Inc. Appoints Martin Shkreli CEO and Announces New Financing

November 18, 2015

KaloBios Confirms Communications with Majority Shareholder Group

November 13, 2015

View Summary KaloBios to Wind Down Operations

Ongoing Clinical Trials

Currently enrolling patients with myelofibrosis or myelodysplastic syndrome in Phase 2 expansion portion of Phase 1/2 clinical trial in hematologic malignancies.

You are now leaving this website. If you would like to continue, click Continue.